B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients

BACKGROUND: B cells are key players in the pathogenesis of rheumatoid arthritis (RA). Although successful in 50–60% of patients with RA, anti-B-cell therapy given as rituximab could be more efficient by identifying potential responders prior to treatment. Positron emission tomography (PET) using rad...

詳細記述

保存先:
書誌詳細
出版年:Arthritis Res Ther
主要な著者: Bruijnen, Stefan, Tsang-A-Sjoe, Michel, Raterman, Hennie, Ramwadhdoebe, Tamara, Vugts, Daniëlle, van Dongen, Guus, Huisman, Marc, Hoekstra, Otto, Tak, Paul-Peter, Voskuyl, Alexandre, van der Laken, Conny
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2016
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5116204/
https://ncbi.nlm.nih.gov/pubmed/27863504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1166-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料